End-of-life practices in 11 German intensive care units : Results from the ETHICUS-2 study.

BACKGROUND: End-of-life care is common in German intensive care units (ICUs) but little is known about daily practice. OBJECTIVES: To study the practice of end-of-life care. METHODS: Prospectively planned, secondary analysis comprising the German subset of the worldwide Ethicus­2 Study (2015-2016) including consecutive ICU patients with limitation of life-sustaining therapy or who died. RESULTS: Among 1092 (13.7%) of 7966 patients from 11 multidisciplinary ICUs, 967 (88.6%) had treatment limitations, 92 (8.4%) died with failed CPR, and 33 (3%) with brain death. Among patients with treatment limitations, 22.3% (216/967) patients were discharged alive from the ICU. More patients had treatments withdrawn than withheld (556 [57.5%] vs. 411 [42.5%], p < 0.001). Patients with treatment limitations were older (median 73 years [interquartile range (IQR) 61-80] vs. 68 years [IQR 54-77]) and more had mental decision-making capacity (12.9 vs. 0.8%), advance directives (28.6 vs. 11.2%), and information about treatment wishes (82.7 vs 33.3%, all p < 0.001). Physicians reported discussing treatment limitations with patients with mental decision-making capacity and families (91.3 and 82.6%, respectively). Patient wishes were unknown in 41.3% of patients. The major reason for decision-making was unresponsiveness to maximal therapy (34.6%). CONCLUSIONS: Treatment limitations are common, based on information about patients' wishes and discussion between stakeholders, patients and families. However, our findings suggest that treatment preferences of nearly half the patients remain unknown which affects guidance for treatment decisions.

Current clinical use of intravenous fosfomycin in ICU patients in two European countries.

PURPOSE: In Europe, intravenous fosfomycin (IV) is used particularly in difficult-to-treat or complex infections, caused by both Gram-positive and Gram-negative pathogens including multidrug-resistant strains. Here, we investigated the efficacy and safety of intravenous fosfomycin under real-life conditions. METHODS: Prospective, multi-center, and non-interventional study in patients with bacterial infections from 20 intensive care units (ICU) in Germany and Austria (NCT01173575). RESULTS: Overall, 209 patients were included (77 females, 132 males, mean age: 59 ± 16 years), 194 of which were treated in intensive care (APACHE II score at the beginning of fosfomycin therapy: 23 ± 8). Main indications (± bacteremia or sepsis) were infections of the CNS (21.5%), community- (CAP) and hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP, 15.3%), bone and joint infections (BJI, 11%), abdominal infections (11%), and bacteremia (10.5%). Most frequently identified pathogens were S. aureus (22.3%), S. epidermidis (14.2%), Enterococcus spp. (10.8%), E. coli (12.3%) and Klebsiella spp. (7.7%). At least one multidrug-resistant (MDR) pathogen was isolated from 51 patients (24.4%). Fosfomycin was administered with an average daily dose of 13.7 ± 3.5 g over 12.4 ± 8.6 days, almost exclusively (99%) in combination with other antibiotics. The overall clinical success was favorable in 81.3% (148/182) of cases, and in 84.8% (39/46) of patients with ≥ 1 MDR pathogen. Noteworthy, 16.3% (34/209) of patients developed at least one, in the majority of cases non-serious, adverse drug reaction during fosfomycin therapy. CONCLUSION: Our data suggest that IV fosfomycin is an effective and safe combination partner for the treatment of a broad spectrum of severe bacterial infections in critically ill patients.

[Non-beneficial therapy and emotional exhaustion in end-of-life care : Results of a survey among intensive care unit personnel]. / Übertherapie und emotionale Erschöpfung in der "end-of-life care" : Ergebnisse einer Mitarbeiterumfrage auf der Intensivstation.

BACKGROUND: End-of-life care (EOLC) in the intensive care unit (ICU) is becoming increasingly more common but ethical standards are compromised by growing economic pressure. It was previously found that perception of non-beneficial treatment (NBT) was independently associated with the core burnout dimension of emotional exhaustion. It is unknown whether factors of the work environment also play a role in the context of EOLC. OBJECTIVE: Is the working environment associated with perception of NBT or clinician burnout? MATERIAL AND METHODS: Physicians and nursing personnel from 11 German ICUs who took part in an international, longitudinal prospective observational study on EOLC in 2015-2016 were surveyed using validated instruments. Risk factors were obtained by multivariate multilevel analysis. RESULTS: The participation rate was 49.8% of personnel working in the ICU at the time of the survey. Overall, 325 nursing personnel, 91 residents and 26 consulting physicians participated. Nurses perceived NBT more frequently than physicians. Predictors for the perception of NBT were profession, collaboration in the EOLC context, excessively high workload (each p ≤ 0.001) and the numbers of weekend working days per month (p = 0.012). Protective factors against burnout included intensive care specialization (p = 0.001) and emotional support within the team (p ≤ 0.001), while emotional exhaustion through contact with relatives at the end of life and a high workload were both increased (each p ≤ 0.001). DISCUSSION: Using the example of EOLC, deficits in the work environment and stress factors were uncovered. Factors of the work environment are associated with perceived NBT. To reduce NBT and burnout, the quality of the work environment should be improved and intensive care specialization and emotional support within the team enhanced. Interprofessional decision-making among the ICU team and interprofessional collaboration should be improved by regular joint rounds and interprofessional case discussions. Mitigating stressful factors such as communication with relatives and high workload require allocation of respective resources.

[Intensive care treatment after aneurysmal subarachnoid hemorrhage]. / Intensivtherapie nach aneurysmatischer Subarachnoidalblutung.

Aneurysmal subarachnoid hemorrhage (SAH) is a devastating disease and nearly one third of patients die in the acute phase. Due to the bleeding event, a hyperactive sympathetic nervous system and an uncontrolled inflammatory response have a profound local and systemic impact on other organ functions. Neuroendocrinological disorders and cardiopulmonary morbidity are dominant. Despite a decrease in hospital mortality for high volume centers, a high proportion of survivors suffer from neurological deficits. Knowledge of the pathophysiology of vasospasms in the later stages of the disease has increased. Anti-inflammatory treatment does not improve the outcome. Nimodipine prophylaxis in the first 96 h after SAH seems to be the only intervention which has been proven to be advantageous in studies; however, nearly every second survivor of SAH suffers from some neurological deficits and more than one third of survivors report depressive episodes or symptoms of posttraumatic stress disorder.

[Stress lesions in the upper gastrointestinal tract]. / Stressläsionen im oberen Gastrointestinaltrakt.

Clinically relevant bleeding in the upper gastrointestinal tract due to stress lesions is a rare event; however, the related mortality may be as high as 13% (van Leerdam, Best Pract Res Clin Gastroenterol 2008; 22:209-224). Most often affected are patients in the intensive care unit (ICU) with impaired perfusion as the protective pathways are critically dependent on a near normal blood flow. Minimal mucosal lesions with a tiny hemorrhage can escalate to severe bleeding as the coagulation potential in the presence of an acidic pH is clearly decreased. Mechanical ventilation and coagulopathy are recognized risk factors and these patients should receive an acid suppressing therapy. Proton pump inhibitors (PPI) and histamine type 2 receptor antagonists (H(2)RA) are equal in their ability to prevent stress-related bleeding. However, the side effects of PPI can cause severe morbidity and therefore H(2)RAs may be the drug of choice for prophylaxis. Endoscopy is recommended as a diagnostic and therapeutic tool for patients with active bleeding. Treatment with PPI in this scenario (before and after endoscopy) may reduce complications by leading to premature hemostasis and reduced recurrence of bleeding.

[Acute perioperative disturbances of renal function. Strategies for prevention and therapy]. / Akute perioperative Störungen der Nierenfunktion: Strategien zur Prävention und Therapie.

The increasing life expectancy in industrial nations leads to an increase in the number of elderly and aged persons treated in hospital. Increasingly more complex operations are being carried out on this group of patients. Renal dysfunction in the preoperative situation increases morbidity and mortality. Acute kidney injury (AKI) is nearly always part of a multi-organ dysfunction syndrome in critically ill patients. The treatment strategy of the AKI should be oriented to the degree of organ dysfunction. However, the stage of organ dysfunction is mostly unknown so that the therapeutically exploitable interval is often missed. The same therapy is practically always used for all patients: administration of fluids and diuretics often under the premise of "the kidneys must be rinsed". A unified classification of the continuation of kidney function disorders using the RIFLE criteria (risk, injury, failure, loss, endstage kidney disease) can assist recognition of early stages of kidney failure in order to react correspondingly with therapeutic measures and to critically question or optimize the use of conservative treatment strategies.

[Intrahospital transport of critically ill patients]. / Innerklinischer Transport des kritisch kranken Patienten.

Transport of critically ill patients from the ICU for diagnostic and therapeutic purposes (e.g. CT, endoscopy, radiological catheter-assisted interventions) is a challenge and has steadily increased over the years. After risk-benefit analysis careful planning is the first step in minimizing the risk of complications. Knowledge and skillful handling of the transport equipment is mandatory to avoid life-threatening incidents as monitoring and therapy have to be continued during the transport. Proper education and experience in critical care medicine are additional characteristics of the transport team. When these prerequisites are fulfilled a "non-transportable" patient is just as unlikely as a "non-anesthetizable" patient.

[Study protocol of the VISEP study. Response of the SepNet study group]. / Studienprotokoll der VISEP-Studie. Entgegnung der SepNet-Studiengruppe.

In the commentary by Zander et al. the authors appear concerned about the methods and results of our, at that time, unpublished sepsis trial evaluating hydroxyethyl starch (HES) and insulin therapy. Unfortunately, the authors' concerns are based on false assumptions about the design, conduct and modes of action of the compounds under investigation. For instance, in our study the HES solution was not used for maintenance of daily fluid requirements, so that the assumption of the authors that this colloid was used "exclusively" is wrong. Moreover, the manufacturer of Hemohes, the HES product we used, gives no cut-off value for creatinine, thus the assumption that this cut-off value was "doubled" in our study is also incorrect. Other claims by the authors such as that lactated solutions cause elevated lactate levels, iatrogenic hyperglycemia and increase O(2) consumption are unfounded. There is no randomized controlled trial supporting such a claim - this claim is neither consistent with our study data nor with any credible published sepsis guidelines or with routine practice worldwide. We fully support open scientific debate. Our study methods and results have now been published after a strict peer-reviewing process and this data is now open to critical and constructive reviewing. However, in our opinion this premature action based on wrong assumptions and containing comments by representatives of pharmaceutical companies does not contribute to a serious, unbiased scientific discourse.

[Aspiration syndrome: epidemiology, pathophysiology, and therapy]. / Aspirationssyndrom : Epidemiologie, Pathophysiologie und Therapie.

Aspiration syndromes are important causes of morbidity and mortality during general anaesthesia as well as in the intensive care unit. Up to 30% of patients with aspiration may develop an acute respiratory distress syndrome, with an attributed mortality of 16%. Although aspiration syndrome is not a frequent event, the anaesthesist must be familiar with the management of this complication and must know the risk factors for it. Discrimination between pneumonitis, an abacterial inflammation, and pneumonia is of utmost importance because treatment strategies differ; for instance, treatment is merely supportive in pneumonitis. This review gives an overview of the epidemiology and pathophysiology of aspiration syndrome, strategies to avoid aspiration, and a brief discussion of treatment concepts.

[Cytochrome P450 enzymes and their role in drug interactions]. / Cytochrom-P450-Enzyme und ihre Bedeutung für Medikamenteninteraktionen.

One of the factors that can alter the response to drugs is the concurrent administration of other drugs. There are several mechanisms by which drugs may interact, but most can be categorised as pharmacokinetic (absorption, distribution, metabolism, excretion), pharmacodynamic, or combined toxicity. Knowledge of the mechanism by which a given drug interaction occurs is often clinically useful and may help to avoid serious adverse events and perioperative morbidity. Although every tissue has some ability to metabolise drugs, the liver is the principal organ of drug metabolism and at the subcellular level the cytochrome P450 enzyme system is the main source of drug interaction. This article reviews the basic principles of drug metabolism and the role of cytochrome P450 in this scenario. Drugs frequently used in anaesthesia and critical care medicine such as benzodiazepines, opioid analgesics, antihypertensive and antiarrhythmic agents, antibiotics and antifungal drugs, antiemetics, histamine-receptor-antagonists, theopylline and paracetamol will be considered. The development of methods and tools which are practical and also economic, are of utmost importance since drug interaction is predictable if the metabolic pathway and the activity (genetic polymorphism) of the enzyme is known.

[Initial experiences with rigid angled optical systems as intubation aids in difficult intubation]. / Erste Erfahrungen mit starren Winkeloptiken als Intubationshilfe bei der schwierigen Intubation.

Referring to a classification by Cormack, difficult laryngoscopy of Grade 3 (only the epiglottis or a part of it can be seen) was simulated in 16 patients by lowering the blade of the laryngoscope, so that the epiglottis was pushed down and thus covered up the vocal cords. The object of the study was to test whether a newly developed rigid endoscope is a useful tool during intubation in cases of laryngoscopical view Grade 3. After simulation of Grade 3 as mentioned above, using a clip, an angle optic was fixed to the vertical part of the blade, so that the movement of the optic in the sagittal level was still possible. If an improvement of the laryngoscopical view was possible, the tracheal tube was inserted via the nasal route until the top of the tube could be seen in the oropharynx. The tracheal tube was inserted into the trachea, under endoscopic control. With this new method, naso-tracheal intubation under endoscopic control in all 16 patients was successful, without affecting the pharynx and the vocal cords.